Loading...
Loading...
Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc.. Spoken Alpha tracks CRDL's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks CRDL's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CRDL.
curl https://api.spokenalpha.com/v1/companies/CRDL| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.33 | $3.39 | +27.8% | -1.0% | +2.0% |
| Q4 FY2026 | $4.88 | $3.61 | +35.2% | +1.7% | +3.2% |
| Q3 FY2026 | $5.04 | $3.62 | +39.3% | -2.8% | -3.4% |
| Q2 FY2026 | $4.55 | $3.45 | +31.8% | +6.6% | +4.4% |
| Q1 FY2025 | $4.94 | $3.74 | +32.0% | +6.2% | +6.4% |
| Q4 FY2025 | $5.11 | $3.65 | +40.0% | +5.3% | +2.7% |
| Q3 FY2025 | $5.17 | $3.69 | +40.0% | +6.9% | +8.0% |
| Q2 FY2025 | $5.21 | $3.79 | +37.5% | -1.3% | -2.8% |
| Q1 FY2024 | $5.13 | $3.76 | +36.5% | -2.4% | -3.1% |
| Q4 FY2024 | $4.67 | $3.62 | +29.1% | +3.5% | +6.3% |